News

Adamas Pharmaceuticals’ vitro study of its triple combination antiviral drug (TCAD) therapy showed greater potency against seasonal and novel H1N1 influenza viruses than currently recommended single or double

Tobira Therapeutics has revealed results from an in-vitro study evaluating TBR-652 in combination with lopinavir (LPV), darunavir (DRV), atazanavir (ATV), tenofovir (TDF), etravirine (ETV), and raltegravir (RAL), using

Alcon has entered into an agreement to acquire ESBATech. Alcon will pay ESBATech shareholders $150m in cash at closing, plus contingent payments of up to $439m based upon

Nektar Therapeutics’ clinical study data demonstrated that the oral tablet formulation of NKTR-118 has favorable systemic bioavailability and a low risk for mediating significant drug-drug interactions. NKTR-118 is

Gilead Sciences (Gilead) has published data from DAR-311 (DORADO), a phase III clinical trial evaluating the company’s once-daily oral endothelin receptor antagonist (ERA) – darusentan, as an add-on

Roche’s two new observational studies concluded that influenza patients treated with Tamiflu had significantly higher survival rates than untreated patients. The studies, examining nearly 1,000 people, analysed outcomes

Merck has studied Isentress in comparison to efavirenz in maintaining viral load suppression to undetectable levels (less than 50 copies/mL), and at improving CD4 cell counts in previously

Forest Laboratories (Forest) has presented new data from a complete analysis of FOCUS 1 and FOCUS 2, two global multicenter phase III studies of ceftaroline for the treatment

Theravance and Astellas have reported that the FDA has approved Vibativ (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI). Vibativ is